In patients with metastatic melanoma before and during anti-PD-1 antibody pembrolizumab treatment, the amount of circulating exosomal PD-L1 may reflect different states of anti-tumor immunity (Fig. 1). This evidence concerns the gene CD274 and neoplasm.